TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
05 Agosto 2024 - 6:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a
conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET
to discuss results for the second quarter of 2024 and provide a
business outlook for 2024. Michael S. Weiss, Chairman and Chief
Executive Officer, will host the call.
In order to participate in the conference call, please call
1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.),
Conference Title: TG Therapeutics Second Quarter Earnings Call. A
live webcast of this presentation will be available on the Events
page, located within the Investors & Media section, of the
Company's website at www.tgtherapeutics.com. An audio recording of
the conference call will also be available for replay at
www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this
period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICSTG Therapeutics is a fully
integrated, commercial stage, biopharmaceutical company focused on
the acquisition, development and commercialization of novel
treatments for B-cell diseases. In addition to a research pipeline
of investigational medicines, TG Therapeutics has received approval
from the U.S. Food and Drug Administration (FDA) for BRIUMVI®
(ublituximab-xiiy) for the treatment of adult patients with
relapsing forms of multiple sclerosis, including clinically
isolated syndrome, relapsing-remitting disease, and active
secondary progressive disease, as well as approval by the European
Commission (EC) and the Medicines and Healthcare Products
Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with
RMS who have active disease defined by clinical or imaging features
in Europe and the United Kingdom, respectively. For more
information, visit www.tgtherapeutics.com, and follow us on X
(formerly Twitter) @TGTherapeutics and on LinkedIn. CONTACT:
Investor Relations
Email: ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option
Media
Relations:Email: media@tgtxinc.comTelephone:
1.877.575.TGTX (8489), Option 6
TG Therapeutics (NASDAQ:TGTX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
TG Therapeutics (NASDAQ:TGTX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024